Trademark Overview
On Thursday, January 4, 2024, a trademark application was filed for ABRIVI THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the ABRIVI THERAPEUTICS trademark a serial number of 98341186. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, January 4, 2024. This trademark is owned by MAPS Public Benefit Corporation. The ABRIVI THERAPEUTICS trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Prescription psychotropic drugs; Midomafetamine (MDMA) preparations for medical purposes; Pharmaceutical preparations for managing and treating mental illnesses and psychiatric, psychological, and neurological disorders and conditions; Psychopharmaceutical preparations for managing and treating diseases, disorders, and conditions related to HPA axis dysregulation, trauma, mood, thought, behavior, and perception; Psychedelic therapeutic preparations for treating and managing PTSD, eating disorders, postpartum depression, alcohol use disorder, opioid and substance use disorder, generalized anxiety disorder, social anxiety disorder, major depressive disorder, and traumatic brain injury.
Medical scientific research and development in the fields of psychotropics, psychedelic-assisted therapy, and psychopharmaceuticals; Providing medical scientific research information in the fields of psychotropics, psychedelic-assisted therapy, and psychopharmaceuticals.
